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Background/Purpose: Elderly lymphomas are usually deﬁned as disease onset at age more than 60 years
according to the criteria of the International Prognostic Index (IPI). IPI, the standard risk stratiﬁcation
system of aggressive lymphoma, was proposed before the introduction of rituximab (a monoclonal
antibody of CD20). While rituximab has markedly improved the outcomes of diffuse large B cell
lymphomas (DLBCL), the appropriateness of IPI has been questioned. Meanwhile, applying modiﬁed IPI
to patients at extreme age has also been suggested in some reports. Hence, this study aims to evaluate
the impact of Elderly-IPI (E-IPI) with cutoff age at 70 years in elderly DLBCL receiving rituximab or not.
Methods: In a tertiary medical center, DLBCL patients older than 60 years were enrolled between January
2000 and December 2009. We excluded patients who did not receive ﬁrst-line chemotherapy with
CEOP/CNOP (cyclophosphamide, epirubicin/mitoxantrone, vincristine, and prednisone) plus rituximab or
not. Patient characteristics and treatment outcomes were analyzed.
Results: In total, 139 patients were included. Age cutoff 70 years was a signiﬁcant impact factor in overall
survival (OS) and progression-free survival (PFS) (p ¼ 0.0044 and 0.0468). For the entire population, age
more than 70 years was demonstrated to be an independent poor predictor in the multivariate analysis
of OS (Hazard ratio: 3.441; 95% CI: 1.761e6.725; p < 0.001) and PFS (Hazard ratio: 1.934; 95% CI: 1.104e
3.388; p ¼ 0.021). In comparison with IPI (p ¼ 0.0001 and 0.2126), E-IPI (p < 0.0001 and p ¼ 0.0285) had
signiﬁcantly greater impact on OS and PFS. In the subgroup analysis, the statistical power of E-IPI and IPI
inﬂuences were superior in the group receiving no rituximab versus the rituximab counterpart.
Conclusion: In DLBCL with old age, age cutoff of 70 years demonstrated promising signiﬁcance in survival
and prognosis. In addition, E-IPI seemed more practical than IPI in the era of rituximab. Because of the
limited numbers of patients analyzed in this retrospective study, further large-scale investigations are
warranted to conﬁrm these results.
Copyright  2012, Asia Paciﬁc League of Clinical Gerontology & Geriatrics. Published by Elsevier Taiwan
Open access under CC BY-NC-ND license.LLC.1. Introduction
Diffuse large B cell lymphoma (DLBCL) is the most common
histological subtype of nonHodgkin’s lymphomas.1,2 The introduc-
tion of rituximab, a monoclonal antibody of CD20, has markedly
improved the clinical outcome and survival of DLBCL. At the same
time, lymphoma onset at age older than 60 years is usually labeled
as elderly lymphoma.3,4 This cutoff is recommended by thend Oncology, Department of
ital, 386, Ta-Chung lst Road,
).
Clinical Gerontology & Geriatrics. Pstandard risk stratiﬁcation system of aggressive lymphomas, the
International Prognostic Index (IPI). Clinically, however, physio-
logical age is more preferred than chronologic age in the decision-
making.5 In elderly DLBCL, the ﬁrst randomized study of CHOP
(cyclophosphamide, doxorubicin, vincristine, and prednisone) with
or without rituximab conﬁrmed the beneﬁts and tolerability of
R-CHOP (rituximab plus CHOP) during long-term follow-up.6 Rit-
uximab seemed to reverse the poor prognostic factor of age. Hence,
the suitability of IPI has been argued in the current era of rituximab.
Some studies have tried to modify parameters of IPI (age and extra-
nodal sites).7,8 For example, modiﬁed age criteria in prognostic
systems have been proposed, such as age-adjusted IPI (AA-IPI) and
elderly IPI (E-IPI) with age cutoff of 70 years. The prognostic
signiﬁcance has been validated respectively.9 Furthermore, E-IPIublished by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
Table 1
Clinical characteristics and treatments of enrolled patients
Characteristics
(median; range)
Classiﬁcations No. of patients (%) p
Age &70 y
(n ¼ 63)
Age＞70 y
(n ¼ 76)
Gender Male 33 (52.4) 63 (82.9) <0.001
Female 30 (47.6) 13 (17.1)
Ann Arbor stage IeII 29 (46) 39 (51.3) 0.610
IIIeIV 34 (54) 37 (48.7)
With B symptoms 8 (12.7) 5 (6.6) 0.252
Extra-nodal sites
involvement
> 1 32 (50.8) 32 (42.1) 0.393
ECOG performance
status
0, 1 50 (79.4) 70 (92.1) 0.045
2e4 13 (20.6) 6 (7.9)
IPI Low 12 (19) 16 (21.1) 0.339
Low-intermediate 23 (36.5) 32 (42.1)
High-intermediate 19 (30.2) 24 (31.6)
High 9 (14.3) 4 (5.3)
E-IPI Low 35 (55.6) 16 (21.1) <0.001
Low-intermediate 19 (30.2) 32 (42.1)
High-intermediate 8 (12.7) 24 (31.6)
High 1 (1.6) 4 (5.3)
LDH (298; 128e1609 ) Normal (&205) 17 (31.5) 15 (24.6) 0.532
Elevated (>205) 37 (68.5) 46 (75.4)
Creatinine (1.0; 0.5e3.1) (mg/dL) 0.9  0.3 1.2  0.5 <0.001
ALT (21; 1e696) (U/L) 119  92 91  36 0.179
First-line
immunochemotherapy
CEOP 24 (38.1) 25 (32.9) 0.183
CNOP 13 (20.6) 20 (26.3)
R-CEOP 25 (39.7) 24 (31.6)
R-CNOP 1 (1.6) 7 (9.2)
ALT¼ alanine transaminase; CEOP¼ cyclophosphamide, epirubicin, vincristine, and
prednisone; CNOP¼ cyclophosphamide, mitoxantrone, vincristine, and prednisone;
ECOG ¼ Eastern Cooperative Oncology Group; E-IPI ¼ Elderly-International
Prognostic Index; IPI¼ International Prognostic Index; LDH¼ lactic dehydrogenase;
R-CEOP ¼ rituximab plus CEOP; R-CNOP ¼ rituximab plus CNOP.
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compared with IPI, AA-IPI and revised IPI.2,7 Despite the above-
mentioned success, little is known regarding rituximab efﬁcacy in
older Chinese and the prognostic signiﬁcance of E-IPI remains
unclear. Therefore, the main purpose of this study was to evaluate
the clinical signiﬁcance of E-IPI in elderly DLBCL in Taiwan.
2. Methods
2.1. Patients
A retrospective cohort of histologically proven DLBCL was
obtained, and those originating from the central nervous system
were excluded. The diagnosis of DLBCL was made according to the
World Health Organization (WHO) classiﬁcation system. Moreover,
patients with age of onset less than 60 years were excluded for
analysis. All enrolled patients received ﬁrst-line chemotherapy
with CEOP/CNOP (cyclophosphamide, epirubicin/mitoxantrone,
vincristine, and prednisone) plus rituximab or not. Among 602
lymphoma patients, 139 patients were included for study between
January 2001 and February 2010. The study was approved by the
Institutional Review Board of Kaohsiung Veterans General Hospital
(VGHKS11-CT8-01).
The clinical stage of DLBCL was deﬁned according to the Ann
Arbor system.10 Staging procedures included physical examination,
complete blood cell count with differential count, blood chemistry,
and computed tomography of the chest, abdomen and pelvis. Bone
marrow aspiration and biopsy were also essential. For every
patient, performance status was determined by the Eastern Coop-
erative Oncology Group scale (ECOG), B symptoms (manifestation
of tumor fever, night sweating or more than 10% of body weight
loss), IPI, and E-IPI were recorded as well. IPI and E-IPI were
composed of ﬁve parameters, including age, performance status,
Ann Arbor stage, extra-nodal site(s), and serum lactic dehydroge-
nase (LDH). Patients with scores 0e1, 2, 3, and 4e5 were classiﬁed
into low, low-intermediate, high-intermediate, and high risk
groups, respectively.9
In this study, active hepatitis was deﬁned by the elevation of
alanine aminotransferase (>100 mg/dL), 3-fold elevation from ALT
baseline, or presence of jaundice (total bilirubin >2.0 mg/dL).
Meanwhile, active hepatitis with HBV DNA higher than 105 copies
per mL was deﬁned as HBV reactivation.11 Treatment responses
were categorized as complete remission (CR): disappearance of all
lesions lasting for 4 weeks; partial remission (PR): at least 50%
reduction of mass; progressive disease (PD): new lesions or
increased size of lesions; and stable disease (SD): those who were
not CR, PR, or PD.
2.2. Statistical analysis
Continuous variables were expressed by median (range), and
categorical data were expressed by frequency and percentage.
Comparisons of categorical variables were done using the Chi-
square test or Fisher’s exact test when appropriate; and compari-
sons between continuous variables were done using the Student t
test. Overall survival (OS) was recorded from the date of diagnosis
to the date of death or last follow-up. Progression-free survival
(PFS) was the time from curative treatment start to the time of
disease progression or persisting complete remission until last
follow-up. OS and PFS were evaluated by the Kaplan-Meier method
and comparisons between groups were done by log-rank test. The
univariate and multivariate analysis of prognostic factors in CR and
survival were estimated with logistic regression and Cox’s
proportional hazards model, respectively. For all tests, a two-tailed
p value less than 0.05 was considered statistically signiﬁcant.Statistical analyses were performed using SPSS software version
12.0 for Windows.
3. Results
3.1. Patient characteristics
Overall, the median age of all patients was 72 years (range: 61 to
84 years). Sixty-three patients were categorized in the elderly
group (61e70 years), and 76 patients were categorized in the very
elderly group (> 70 years). Being a veteran hospital, males were
predominant in the very elderly group (p < 0.001). In the study
sample, borderline signiﬁcance of better performance status was
also noted in the very elderly group (p ¼ 0.0045). Except for the
renal function test (p < 0.001), the other baseline characteristics
and comorbidities were similar between the groups (Table 1). Age
grouping was statistically associated with risk entities, and the
elderly group was signiﬁcantly more likely to have low risk
according to E-IPI (p < 0.001).
Due to the lack of doxorubicin in the study hospital, epirubicin
(or mitoxantrone) was used instead in CEOP (or CNOP) regimens
rather than CHOP regimen. Among the ﬁrst-line treatments of all
patients, 35.3% (n ¼ 49) were administered with CEOP, 35.3%
(n ¼ 49) with R-CEOP, 23.7% (n ¼ 33) with CNOP, and 5.8% (n ¼ 8)
with R-CNOP. Table 1 also summarizes comparisons of treatment
selections between the groups, but similar distribution was noted
in all the treatment selections. Moreover, the elderly group received
signiﬁcantly more cycles of chemotherapy than the very elderly
counterpart (5.5  2.5 cycles vs. 4.5  2.2 cycles; p ¼ 0.017).
Table 2
Adverse events of treatment
Complications No. of patients (%)
Age &70 y (n ¼ 63) Age＞70 y (n ¼ 76) p
Neutropenic fever 16 (25.4) 25 (32.9) 0.357
Acute hepatitis 17 (27) 14 (18.4) 0.306
Herpes zoster 2 (3.2) 0 (0) 0.204
Congestive heart failure 1 (1.6) 2 (2.6) 1.000
HBV reactivation 1 (1.6) 2 (2.6) 1.000
Gastrointestinal bleeding 1 (1.6) 2 (2.6) 1.000
HBV ¼ hepatitis B virus.
Fig 1. Overall survival (OS) and progression-free survival (PFS) in whole populations. (A, B
difference of 2-year survival rates was more obvious between low and low-intermediate gro
not (p ¼ 0.2126). Two-year PFS was converted to be correlative with risk level between low
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Themedian follow-up of all patients was 17.0months (range, 0.4
to 118.8 months). During the observation periods, 60 patients
(43.2%) died and 52 patients (37.4%) had disease progress or
relapse. The death rate was signiﬁcantly higher in the very
elderly group (51.3% vs. 33.3%; p ¼ 0.040), but the percentage of
patients with PD was similar in both groups (38.2% vs. 36.5%;
p ¼ 0.862). The most common causes of death were infections
(61.7%) and disease progression (18.3%). Deaths related to probable
immunochemotherapy-associated adverse events were few, such) Both IPI and E-IPI signiﬁcantly impacted the OS (p ¼ 0.0001 and p < 0.0001). The
ups by E-IPI. (C, D) E-IPI was a signiﬁcant impact factor of PFS (p ¼ 0.0285), but IPI was
and low-intermediate risk groups.
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titis B with acute exacerbation (5.0%). No patient died of congestive
heart failure.
The clinical responses to treatment were similar between the
groups where CR and PR rates were 66.7% and 26.7% in the elderly
group and 55.8% and 37.2% in the very elderly group (p ¼ 0.495). In
the multivariate analysis, low level of lactate dehydrogenase (LDH)
at diagnosis (Relative risk: 0.207; 95% CI: 0.086e0.500; p < 0.001)
was the single signiﬁcant predictor of CR. Compared to the very
elderly group, the elderly group had signiﬁcantly better OS (1- year
OS 85.2% and 2-year OS 78.4% vs. 63.0% and 47.9%, p ¼ 0.0044).
Rather, the PFS showed only marginal beneﬁt in the elderly group
(1-year PFS 82.3% and 2-year PFS 70.3% vs. 62.3% and 43.3%,
p¼ 0.0468). Despite different gender composition between groups,
no signiﬁcant impact was noted in OS or PFS (p ¼ 0.1598 and
0.0843). The adverse events of treatments were similarly distrib-
uted in the two subgroups (Table 2).
According to criteria of IPI and E-IPI, patients were successfully
divided into four risk groups of OS (p ¼ 0.0001 and p < 0.0001,
respectively). Instead of IPI (p ¼ 0.2126), however, only E-IPI
signiﬁcantly impacted PFS (p ¼ 0.0285). Two-year survival rate of
OS and PFS stratiﬁed by IPI and E-IPI are also shown in Fig. 1. The
distance of 2-year OS rate between low and low-intermediate risk
groups was ampliﬁed in E-IPI. Rather than IPI, the 2-year PFS was
found to be correlative with low and low-intermediate risk groupsFig 2. Overall survival rates (OS) in subgroup analysis. (A, B) E-IPI signiﬁcantly impacted the
IPI and E-IPI (p < 0.0001 and p < 0.0001) were signiﬁcant impact factors of OS in patients w
E-IPI.of E-IPI. In short, E-IPI had greater impact on both OS (p< 0.0001 vs.
p ¼ 0.0001) and PFS (p ¼ 0.0285 vs. 0.2126) compared with IPI.
Furthermore, survival impact of both IPI (OS, p < 0.0001 vs.
p¼ 0.0891; PFS, p¼ 0.0100 vs. 0.4532) and E-IPI (OS, p< 0.0001 vs.
p ¼ 0.0031; PFS, p < 0.0001 vs. 0.2904) were more signiﬁcant in
patients without rituximab than those with rituximab. In subgroup
analyses of rituximab and no rituximab, E-IPI also demonstrated
superior statistical signiﬁcance than IPI in either OS or PFS
(Figs. 2, 3).
In the multivariate analysis of E-IPI parameters, age, stage,
performance status, and LDH were signiﬁcant predictors of OS.
Rather, age and stage were independently prognostic factors of PFS.
Hence, age more than 70 years was conﬁrmed to be a signiﬁcantly
poor prognostic factor in the multivariate analysis of OS (Hazard
ratio: 3.441; 95% CI: 1.761e6.725; p< 0.001) and PFS (Hazard ratio:
1.934; 95% CI: 1.104e3.388; p ¼ 0.021) (Table 3).
4. Discussion
The risk stratiﬁcation system of IPI for aggressive lymphomas
was established in 1993, before the era of rituximab.9 The appli-
cation of IPI was argued until supporting evidence came from the
meta-analysis of large-scale randomized control studies,12
although some pitfalls had been criticized.13 Actually, the search
for an optimal prognostic system of DLBCL is a never-ending issueOS in the rituximab group (p ¼ 0.0031), but IPI did not (p ¼ 0.0891). (C, D) Instead, both
ithout rituximab. In comparison with IPI, more diverse survival cure was revealed by
Fig 3. Progression free survival (PFS) in subgroup analysis. (A, B) For patients receiving rituximab, IPI and E-IPI did not signiﬁcantly impact the PFS (p ¼ 0.4532 and 0.2904). (C, D) In
no rituximab group were IPI and E-IPI signiﬁcantly affected PFS (p ¼ 0.0100 and p < 0.0001, respectively). No matter with or without rituximab group, E-IPI demonstrated
statistically superior signiﬁcance than IPI.
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patient characteristics.8,14 Age more than 60 years deﬁned as old
age in the risk stratiﬁcation system by the International Non-
Hodgkin’s Lymphoma Prognostic Factors Project is generally
agreed, but the age criteria need to be modiﬁed according to social,
cultural, geographical, and chronological backgrounds.3 Although
age is a simple and practical concept in the lymphoma risk strati-
ﬁcation system, it deserves more extensive considerations whenTable 3
Univariate and multivariate analysis of parameters of E-IPI
Univariate analysis
HR 95% CI
Overall survival
Age > 70 2.140 1.253e3.654
Stage IIIeIV 2.240 1.308e3.834
ECOG PS > 1 2.876 1.424e5.806
LDH > normal 3.003 1.343e6.715
Extra-nodal sites > 1 2.001 1.174e3.413
Progression-free survival
Age > 70 1.737 1.001e3.012
Stage IIIeIV 1.956 1.123e3.409
ECOG PS > 1 0.627 0.152e2.593
LDH > normal 1.695 0.822e3.493
Extra-nodal sites > 1 1.217 0.636e2.328
CI ¼ conﬁdence interval; ECOG ¼ Eastern Cooperative Oncology Group; HR ¼ hazard ratreatment strategy has been changed and life expectancy has been
prolonged nowadays. While E-IPI was proven to be an efﬁcient
prognostic system under immunochemotherapy with R-CHOP in
the previous report,7 the present study was the ﬁrst to report the
comparison of values of E-IPI before and after the addition of rit-
uximab. The result echoed the concept that IPI was more suitable in
patients receiving no rituximab since rituximab might reduce the
impact of some adverse risk factors. A similar result was also shownMultivariate analysis
p HR 95% CI p
0.005 3.441 1.761e6.725 <0.001
0.003 2.226 1.199e4.131 0.011
0.003 5.712 2.450e13.316 <0.001
0.007 3.089 1.349e7.070 0.008
0.011 d d d
0.050 1.934 1.104e3.388 0.021
0.018 2.146 1.220e3.773 0.008
0.519 d d d
0.153 d d d
0.553 d d d
tio; LDH ¼ lactic dehydrogenase; PS ¼ performance status.
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than IPI. Since rituximab was recommended as an essential
component in ﬁrst-line treatment and IPI played a weaker role in
predicting their outcomes, E-IPI was a reasonable alternative choice
of the prognostic system in the rituximab era.
In the present study, patients were divided into different risk
groups according to IPI. But the distribution was similar in the two
groups (Table 1; p ¼ 0.339). Although the prognostic signiﬁcance of
IPI was clearly shown in OS (p ¼ 0.0001), it was not shown in PFS
(p ¼ 0.2126). On the contrary, a signiﬁcantly higher percentage of
low risk groups stratiﬁed by E-IPI was noted in the elderly group
(p < 0.001). E-IPI was a deﬁnite impact factor in both OS and PFS
(p < 0.0001 and 0.0285). The diverse survival curve was focused on
the low and low-intermediate risk groups, implying the chief
advantage of E-IPI (Fig. 1). Hence, adjusting the cutoff age to 70
years in IPI was further supported by these results.
The clinical beneﬁts of immunochemotherapy in old age DLBCL
are well documented and it has been recommended to be the
standard frontline treatment.15e17 Causes of poorer treatment
response in elderly lymphomas are complex. Rather than intrinsic
tumor resistance, the main possibilities are supposed to be asso-
ciated with comorbidities, declined function reserve, inadequate
intensity or density of treatments, and relative immune dysfunc-
tion in the eradication of residual diseases.3,5 Nevertheless, frail
older patients may not be able to tolerate aggressive treatments,
which can be identiﬁed by comprehensive geriatric assessment.18,19
In this study, patients in the very elderly group with poorer renal
functionwere less likely to receive chemotherapy, as well as the full
course of ﬁrst-line chemotherapy, which may result in different
treatment outcomes. In fact, the very elderly group was highly
selective of patients with good performance status (92.1%). Hence,
there is still space for the improvement of elderly DLBCL treat-
ments, especially in the selection of eligible immunochemotherapy
candidates.
However, there are some limitations in this retrospective study.
First, there were somemissing data and the follow-up durationwas
not long enough. Second, incomprehensive parameters were
analyzed since serological, molecular, cytogenetic, and pathological
markers have been proven prognostic in the previous studies.
Third, the intensity of immunochemotherapy was adjusted by
physicians and the data was unavailable here. It might be an
important confounding factor in the outcomes.
In conclusion, age cutoff of 70 years seemed more practical in
elderly DLBCL receiving rituximab. In comparison with IPI, E-IPI
demonstrated superior statistical signiﬁcance in risk stratiﬁcation
and survival impact. The main advantage of E-IPI was distinguish-
ing low and low-intermediate risk groups. Because of the limited
numbers of patients analyzed in this retrospectively study, further
large-scale investigations are warranted to conﬁrm these results.References
1. Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse
large B-cell lymphoma. CA Cancer J Clin 2010;60:393e408.
2. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The
revised International Prognostic Index (R-IPI) is a better predictor of outcome
than the standard IPI for patients with diffuse large B-cell lymphoma treated
with R-CHOP. Blood 2007;109:1857e61.
3. Gutierrez A, Mestre F, Perez-Manga G, Rodriguez J. Diffuse large B-cell
lymphoma in the older. Crit Rev Oncol Hematol 2011;78:59e72.
4. Coifﬁer B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP
chemotherapy plus rituximab compared with CHOP alone in elderly patients
with diffuse large B-cell lymphoma. N Engl J Med 2002;346:235e42.
5. Pfreundschuh M. How I treat elderly patients with diffuse large B-cell
lymphoma. Blood 2010;116:5103e10.
6. Coifﬁer B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S,
et al. Long-term outcome of patients in the LNH-98.5 trial, the ﬁrst randomized
study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL
patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood
2010;116:2040e5.
7. Advani RH, Chen H, Habermann TM, Morrison VA, Weller EA, Fisher RI, et al.
Comparison of conventional prognostic indices in patients older than 60 years
with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup
Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in
an elderly prognostic index (E-IPI). Br J Haematol 2010;151:143e51.
8. Yoo C, Kim S, Sohn BS, Kim JE, Yoon DH, Huh J, et al. Modiﬁed number of
extranodal involved sites as a prognosticator in R-CHOP-treated patients with
disseminated diffuse large B-cell lymphoma. Korean J Intern Med 2010;25:
301e8.
9. A predictive model for aggressive non-Hodgkin’s lymphoma. The International
Non-Hodgkin’s lymphoma prognostic factors project. N Engl J Med 1993;329:
987e94.
10. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the
Committee on Hodgkin’s disease staging classiﬁcation. Cancer Res 1971;31:
1860e1.
11. Pei SN, Chen CH, Lee CM, Wang MC, Ma MC, Hu TH, et al. Reactivation of
hepatitis B virus following rituximab-based regimens: a serious complication
in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 2010;89:
255e62.
12. Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, et al.
Standard International Prognostic Index remains a valid predictor of outcome
for patients with aggressive CD20þ B-cell lymphoma in the rituximab era.
J Clin Oncol 2010;28:2373e80.
13. Tay K, Tai D, Tao M, Quek R, Ha TC, Lim ST. Relevance of the International Prog-
nostic Index in the rituximab era. J Clin Oncol 2011;29:e14. author reply e5.
14. Bari A, Marcheselli L, Sacchi S, Marcheselli R, Pozzi S, Ferri P, et al. Prognostic
models for diffuse large B-cell lymphoma in the rituximab era: a never-ending
story. Ann Oncol 2010;21:1486e91.
15. Coifﬁer B. Immunochemotherapy: the new standard in aggressive non-
Hodgkin’s lymphoma in the elderly. Semin Oncol 2003;30:21e7.
16. Coifﬁer B, Salles G. Immunochemotherapy is the standard of care in elderly
patients with diffuse large B-cell lymphoma. Blood 2004;104:1584e5. author
reply 5e6.
17. Wang M, Burau KD, Fang S, Wang H, Du XL. Ethnic variations in diagnosis,
treatment, socioeconomic status, and survival in a large population-based
cohort of elderly patients with non-Hodgkin lymphoma. Cancer 2008;113:
3231e41.
18. Tucci A, Ferrari S, Bottelli C, Borlenghi E, Drera M, Rossi G. A comprehensive
geriatric assessment is more effective than clinical judgment to identify elderly
diffuse large cell lymphoma patients who beneﬁt from aggressive therapy.
Cancer 2009;115:4547e53.
19. Kobayashi Y, Miura K, Hojo A, Hatta Y, Tanaka T, Kurita D, et al. Charlson
Comorbidity Index is an independent prognostic factor among elderly patients
with diffuse large B-cell lymphoma. J Cancer Res Clin Oncol 2011;137:1079e84.
